[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
May 2, 2001

Two Ophthalmic Solutions

Author Affiliations
 

Not Available

Not Available

JAMA. 2001;285(17):2186. doi:10.1001/jama.285.17.2186-JFD10004-2-1

The FDA has approved two new drugs, bimatoprost ophthalmic solution, 0.03% (Lumigan, Allergan Inc, Irvine, Calif), and travoprost ophthalmic solution, 0.004% (Travatan, Alcon Universal Ltd, Fort Worth, Tex), for reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Both products provide additional alternatives for patients who are intolerant of other IOP-lowering medications or insufficiently responsive (failure to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication.

First Page Preview View Large
First page PDF preview
First page PDF preview
×